Abstract
The inside cover picture displays a potent and selective S1PR1 agonist 9i as a promising candidate for the treatment of ulcerative colitis. In this work, compound 9i is obtained through rational drug design based on BAF312. The findings show that compound 9i demonstrates excellent activity to S1PR1 in vitro and remarkable anti‐inflammatory efficacy in a DSS‐induced mouse model of UC. More details are given in the article by Li et al. on page 2625—2632.image
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
